Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons | Zendy

David L. Thomas | Zendy; John G. Bartlett | Zendy; Marion G. Peters | Zendy; Kenneth E. Sherman | Zendy; Mark S. Sulkowski | Zendy; Paul A. Pham | Zendy

Open Access

Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons

Author(s) -

David L. Thomas,

John G. Bartlett,

Marion G. Peters,

Kenneth E. Sherman,

Mark S. Sulkowski,

Paul A. Pham

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir882

Subject(s) - medicine , hepatitis c virus , protease inhibitor (pharmacology) , virology , hepatitis c , protease , human immunodeficiency virus (hiv) , virus , food and drug administration , immunology , hepatitis , hepacivirus , viral load , pharmacology , antiretroviral therapy , biology , enzyme , biochemistry

In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research